Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan

Vaccine

Volumn 28, Issue 50, 2010, Pages 7923-7932

  de Blasio, Birgitte Freiesleben ^a,c   Kasymbekova, Kaliya ^b   Flem, Elmira ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b Ministry of Health   (Kyrgyzstan)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Dynamic model; Herd immunity; Rotavirus; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; DEVELOPING COUNTRY; ECONOMIC ASPECT; GASTROENTERITIS; HEALTH CARE POLICY; HERD IMMUNITY; HOME CARE; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION PREVENTION; KYRGYZSTAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SCHOOL CHILD; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GASTROENTERITIS; HOSPITALIZATION; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INFANT; KYRGYZSTAN; MODELS, BIOLOGICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; YOUNG ADULT;

EID: 78650238955     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.070     Document Type: Article

References (43)

1. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(February (2)):304-306.
2. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301(June (21)):2243-2251.
3. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(January (4)):289-298.
4. Martin A., Batty A., Roberts J., Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009, 33(July (16)):4520-4528.
5. Huet F., Largeron N., Trichard M., Miadi-Fargier H., Jasso-Mosqueda G. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine 2007, 25(August (34)):6348-6358.
6. Kim S.Y., Goldie S.J., Salomon J.A. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009, 9:29.
7. Dhont P., Trichard M., Largeron N., Rafia R., Benard S. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J Med Econ 2008, 11(3):431-448.
8. Constenla D., Perez-Schael I., Rheingans R.D., Antil L., Salas H., Yarzabal J.P. Assessment of the economic impact of the antiretroviral vaccine in Venezuela. Rev Panam Salud Publica 2006, 20(October (4)):213-222.
9. Constenla D.O., Linhares A.C., Rheingans R.D., Antil L.R., Waldman E.A., da Silva L.J. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008, 26(December (4)):388-396.
10. Valencia-Mendoza A., Bertozzi S.M., Gutierrez J.P., Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008, 8:103.
11. Shim E, Banks H, Castillo-Chavez C. Seasonality of rotavirus infection with its vaccination. Modeling the Dynamics of Human Diseases: Emerging Paradigms and Challenges; 2006.
12. Shim E., Feng Z., Martcheva M., Castillo-Chavez C. An age-structured epidemic model of rotavirus with vaccination. J Math Biol 2006, 53(October (4)):719-746.
13. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325(July (5938)):290-294.
14. Flem E.T., Latipov R., Nurmatov Z.S., Xue Y., Kasymbekova K.T., Rheingans R.D. Costs of diarrheal disease and cost-effectiveness of rotavirus vaccination in Kyrgyzstan. J Infect Dis 2009, 200(November (Suppl 1)):S195-S202.
15. Flem E.T., Kasymbekova K.T., Vainio K., Gentsch J., Abdikarimov S.T., Glass R.I., et al. Rotavirus infection in hospitalized children and estimates of disease burden in Kyrgyzstan, 2005-2007. Vaccine 2009, 27(November (Suppl 5)):F35-F39.
16. Chandran A., Heinzen R.R., Santosham M., Siberry G.K. Nosocomial rotavirus infections: a systematic review. J Pediatr 2006, 149(October (4)):441-447.
17. Mrukowicz J., Szajewska H., Vesikari T. Options for the prevention of rotavirus disease other than vaccination. J Pediatr Gastroenterol Nutr 2008, 46(May (Suppl 2)):S32-S37.
18. National Statistical Committee of the Kyrgyz Republic, UNICEF/CO. Multiple Indicator Cluster Survey 2006, Kyrgyz Republic. Final Report. Bishkek, Kyrgyzstan: National Statistical Committee of the Kyrgyz Republic; 2007.
19. Field's virology 2005, Lippincott Williams & Wilkins. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
20. Kapikian A.Z., Wyatt R.G., Levine M.M., Yolken R.H., VanKirk D.H., Dolin R., et al. Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 1983, 147(January (1)):95-106.
21. Parashar U.D., Bresee J.S., Gentsch J.R., Glass R.I. Rotavirus. Emerg Infect Dis 1998, 4(October (4)):561-570.
22. Anderson E.J., Weber S.G. Rotavirus infection in adults. Lancet Infect Dis 2004, 4(February (2)):91-99.
23. Hochwald C., Kivela L. Rotavirus vaccine, live, oral, tetravalent (RotaShield). Pediatr Nurs 1999, 25(March (2)):203-204. 207.
24. White L.J., Buttery J., Cooper B., Nokes D.J., Medley G.F. Rotavirus within day care centres in Oxfordshire, UK: characterization of partial immunity. J R Soc Interface 2008, 5(December (29)):1481-1490.
25. Chiba S., Yokoyama T., Nakata S., Morita Y., Urasawa T., Taniguchi K., et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986, 2(August (8504)):417-421.
26. Velazquez F.R. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009, 28(March (3 Suppl)):S54-S56.
27. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996, 335(14):1022-1028.
28. UN. United Nations Secretariat, World Population Prospetcs. 2009. 29-6-2009. Ref Type: Internet Communication.
29. Kang G., Iturriza-Gomara M., Wheeler J.G., Crystal P., Monica B., Ramani S., et al. Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: correlation with clinical severity in children in South India. J Med Virol 2004, 73(May (1)):118-122.
30. Zagheni E., Billari F.C., Manfredi P., Melegaro A., Mossong J., Edmunds W.J. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008, 168(November (9)):1082-1090.
31. Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008, 5(March (3)):e74.
32. Wallinga J., Teunis P., Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol 2006, 164(November (10)):936-944.
33. Dennehy P.H. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 2000, 19(October (10 Suppl)):S103-S105.
34. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22(July (21-22)):2836-2842.
35. WHO. Kyrgyzstan reported immunization coverage. WHO 2009 June 1 [cited 2009 Jul 1]; available from: URL: http://www.who.int/vaccines/globalsummary/immunization.
36. Akmatov M.K., Kretzschmar M., Kramer A., Mikolajczyk R.T. Determinants of childhood vaccination coverage in Kazakhstan in a period of societal change: implications for vaccination policies. Vaccine 2007, 25(February (10)):1756-1763.
37. Burnham K.P., Anderson D.R. Model selection and multimodel inference-a practical information-theoretic approach 2002, Springer-Verlag, New York. 2nd ed.
38. Linhares A.C., Velazquez F.R., Perez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(April (9619)):1181-1189.
39. Musher D.M., Musher B.L. Contagious acute gastrointestinal infections. N Engl J Med 2004, 351(December (23)):2417-2427.
40. Diekmann O., Heesterbank J. Mathematical epidemiology of infectious diseases 2000, John Wiley & Sons, Chichester, England.
41. Atchison C., Lopman B., Edmunds W.J. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010, 28(April (18)):3118-3126.
42. Parashar U.D., Glass R.I. Rotavirus vaccines-early success, remaining questions. N Engl J Med 2009, 360(March (11)):1063-1065.
43. Van E.T., Soriano-Gabarro M., Debrus S., Claire N.E., Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010, 138(June (6)):884-897.